Paris and London, November 29 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European ...
Paris and London (ots/PRNewswire) - In the news release, "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read "ONGLYZA(R) Becomes the First ...
Paris and London (ots/PRNewswire) - Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca.com) today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is ...
Stockholm (ots/PRNewswire) - Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca-us.com) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride ...
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were ...
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus diet and exercise. This study found that the addition of ...
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated ...
Princeton, New Jersey and London (ots/PRNewswire) - Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA(TM) (saxagliptin) 5 mg per day achieved the primary objective of ...
Paris and London (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) (LSE: AZN) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union. Onglyza is indicated as a once-daily 5 mg oral tablet dose ...
Paris and London (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (LSE: AZN) today announced that their marketing authorisation application for ONGLYZA(TM) (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, ...
Rome (ots/PRNewswire) - - FOR EUROPEAN MEDICAL MEDIA ONLY - New Data Presented for the First Time at EASD 2008 - Saxagliptin With Metformin as Initial Combination Therapy Lowered A1C - Improvements Demonstrated Across Key Measures of Glucose Control Studied in Treatment-Naïve People With Type 2 ...
Rome (ots/PRNewswire) - - FOR EUROPEAN MEDICAL MEDIA ONLY - New Data Presented for the First Time at EASD 2008 - Saxagliptin With Metformin as Initial Combination Therapy Lowered A1C - Improvements Demonstrated Across Key Measures of Glucose Control Studied in Treatment-Naïve People With Type 2 ...